Abstract
Despite significant efforts in diagnosing and treating lung cancer, therapeutic resistance remains a major unresolved clinical and scientific problem. Cancer stem cells (CSCs) are thought to be responsible for the failure of current chemotherapy of lung cancer. The concept of CSCs has radically changed the view of cancer therapy. Today a majority of current treatment modalities target the differentiated cancer cells and avoid the drug resistant cancer-initiating stem cells. This review summarizes our understanding of lung CSCs and their role in metastasis formation and growth of non- small-cells lung cancer (NSCLC). High tumorigenic and metastatic properties of lung CSCs are associated with the efficient cytokine network production and with the specific signaling pathways. This review underlines the experimental evidence indicating that the stem cell factor (SCF) and its receptor c-kit (CD117) play an important role in survival and proliferation of lung CSCs. Thus, molecularly targeting key cytokine network axes of such highly tumorigenic and metastatic CSCs must be considered for improving the current anti-cancer strategy efficacy. Standard chemotherapy in combination with specific axis of cytokine network targeting, such as SCF-c-kit, could eliminate both bulk tumor cells and CSCs, and therefore to be truly curative therapies. This review provides a summary of some of the developments in the field of lung CSCs targeting and highlights aspects which could help in the drug discovery process.
Keywords: Human lung cancer stem cells, Drug resistance, Cytokine network, Cancer stem cell targeted therapy
Anti-Cancer Agents in Medicinal Chemistry
Title: Lung Cancer Stem Cells as a Target for Therapy
Volume: 10 Issue: 2
Author(s): Elieser Gorelik, Anna Lokshin and Vera Levina
Affiliation:
Keywords: Human lung cancer stem cells, Drug resistance, Cytokine network, Cancer stem cell targeted therapy
Abstract: Despite significant efforts in diagnosing and treating lung cancer, therapeutic resistance remains a major unresolved clinical and scientific problem. Cancer stem cells (CSCs) are thought to be responsible for the failure of current chemotherapy of lung cancer. The concept of CSCs has radically changed the view of cancer therapy. Today a majority of current treatment modalities target the differentiated cancer cells and avoid the drug resistant cancer-initiating stem cells. This review summarizes our understanding of lung CSCs and their role in metastasis formation and growth of non- small-cells lung cancer (NSCLC). High tumorigenic and metastatic properties of lung CSCs are associated with the efficient cytokine network production and with the specific signaling pathways. This review underlines the experimental evidence indicating that the stem cell factor (SCF) and its receptor c-kit (CD117) play an important role in survival and proliferation of lung CSCs. Thus, molecularly targeting key cytokine network axes of such highly tumorigenic and metastatic CSCs must be considered for improving the current anti-cancer strategy efficacy. Standard chemotherapy in combination with specific axis of cytokine network targeting, such as SCF-c-kit, could eliminate both bulk tumor cells and CSCs, and therefore to be truly curative therapies. This review provides a summary of some of the developments in the field of lung CSCs targeting and highlights aspects which could help in the drug discovery process.
Export Options
About this article
Cite this article as:
Gorelik Elieser, Lokshin Anna and Levina Vera, Lung Cancer Stem Cells as a Target for Therapy, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (2) . https://dx.doi.org/10.2174/187152010790909308
DOI https://dx.doi.org/10.2174/187152010790909308 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Methods and Research Progress in Nanomaterials Risk Assessment
Current Drug Metabolism Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery NF-κB Signaling Pathway Inhibitors as Anticancer Drug Candidates
Anti-Cancer Agents in Medicinal Chemistry Meta-analysis Reveals No Association of DNMT3B -149 C>T Gene Polymorphism With Overall Cancer Risk
Current Genomics Notch-Associated MicroRNAs in Cancer
Current Drug Targets Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance
Current Drug Metabolism The Molecular Basis of Notch Signaling Regulation: A Complex Simplicity
Current Molecular Medicine Targeting DNA Minor Groove by Hybrid Molecules as Anticancer Agents
Current Medicinal Chemistry Cinnamic Acid Derivatives as Anticancer Agents-A Review
Current Medicinal Chemistry Phenylbutyric Acid: Simple Structure - Multiple Effects
Current Pharmaceutical Design Immunotherapeutic Approaches in Pancreatic Adenocarcinoma: Current Status and Future Perspectives
Current Molecular Pharmacology Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Editorial (Thematic Issue: Effective and Promising Treatments for Neurological Disorders and Cancer)
Current Pharmaceutical Design Genotoxicity of Different Nanocarriers: Possible Modifications for the Delivery of Nucleic Acids
Current Drug Discovery Technologies Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry Clinical Trials Targeting Advanced Cancers by Active Immunization of T-cell Defined Tumor Antigens
Current Pharmaceutical Design Contribution of Efflux Pump Activity to the Delivery of Pulmonary Therapeutics
Current Drug Metabolism Laccases in Pharmaceutical Chemistry: A Comprehensive Appraisal
Mini-Reviews in Organic Chemistry Anti-Cancer Potential of a Novel SERM Ormeloxifene
Current Medicinal Chemistry Tumor Markers in Patients with Benign and Malignant Pulmonary Diseases; Competitive Evaluation of ProGRP, NSE and Cyfra 21-1
Recent Patents on Biomarkers